Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Autor: G. Martini, D. Ciardiello, V. Famiglietti, D. Rossini, C. Antoniotti, T. Troiani, S. Napolitano, L. Esposito, T. P. Latiano, E. Maiello, M. Del Re, S. Lonardi, G. Aprile, D. Santini, G. Masi, A. Avallone, N. Normanno, F. Pietrantonio, C. Pinto, F. Ciardiello, C. Cremolini, E. Martinelli

Publikováno v: Cancer Medicine, Vol 12, Iss 8, Pp 9392-9400 (2023)

Abstract The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti�

Externí odkaz: https://doaj.org/article/873b18bc13684635ba23c522361014ef

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis

Autor: J. Ventriglia, A. Petrillo, M. Huerta Alváro, M. M. Laterza, B. Savastano, V. Gambardella, G. Tirino, L. Pompella, A. Diana, F. Iovino, T. Troiani, E. Martinelli, F. Morgillo, M. Orditura, A. Cervantes, F. Ciardiello, F. De Vita

Publikováno v: Gastroenterology Research and Practice, Vol 2018 (2018)

Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemothera

Externí odkaz: https://doaj.org/article/fd62ed78bce447b9ab0bbccb5db83ef5

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Autor: C. Cardone, A. De Stefano, G. Rosati, A. Cassata, L. Silvestro, M. Borrelli, E. Di Gennaro, C. Romano, A. Nappi, N. Zanaletti, F. Foschini, R. Casaretti, F. Tatangelo, S. Lastoria, M. Raddi, D. Bilancia, V. Granata, S. Setola, A. Petrillo, C. Vitagliano, P. Gargiulo, L. Arenare, A. Febbraro, E. Martinelli, F. Ciardiello, P. Delrio, A. Budillon, M.C. Piccirillo, A. Avallone

Background: Maintaining angiogenesis inhibition and switching the chemotherapy backbone represent the current second-line therapy in patients with RAS-mutant metastatic colorectal cancer (mCRC). Regorafenib, an oral multikinase inhibitor, prolonged o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4de1274e1101a4f09f6c89979c165bf
https://hdl.handle.net/11591/486125

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Autor: Lucia Del Mastro, Francesca Poggio, Eva Blondeaux, Sabino De Placido, Mario Giuliano, Valeria Forestieri, Michelino De Laurentiis, Adriano Gravina, Giancarlo Bisagni, Anita Rimanti, Anna Turletti, Cecilia Nisticò, Angela Vaccaro, Francesco Cognetti, Alessandra Fabi, Simona Gasparro, Ornella Garrone, Maria Grazia Alicicco, Ylenia Urracci, Mauro Mansutti, Paola Poletti, Pierpaolo Correale, Claudia Bighin, Fabio Puglisi, Filippo Montemurro, Giuseppe Colantuoni, Matteo Lambertini, Luca Boni, M Venturini, A Abate, S Pastorino, G Canavese, C Vecchio, M Guenzi, M Lambertini, A Levaggi, S Giraudi, V Accortanzo, C.A. Floris, E Aitini, G Fornari, S Miraglia, G Buonfanti, M.C. Cherchi, F Petrelli, A Vaccaro, E Magnolfi, A Contu, R Labianca, A Parisi, C Basurto, F Cappuzzo, M Merlano, S Russo, M Mansutti, E Poletto, M Nardi, D Grasso, A Fontana, L Isa, M Comandè, L Cavanna, S Iacobelli, S Milani, G Mustacchi, S Venturini, A.F. Scinto, M.G. Sarobba, P Pugliese, A Bernardo, I Pavese, M Coccaro, B Massidda, M.T. Ionta, A Nuzzo, L Laudadio, V Chiantera, R Dottori, M Barduagni, F Castiglione, F Ciardiello, V Tinessa, A Ficorella, L Moscetti, I Vallini, G Giardina, R Silva, M Montedoro, E Seles, F Morano, G Cruciani, V Adamo, A Pancotti, V Palmisani, A Ruggeri, E Cammilluzzi, F Carrozza, M D'Aprile, M Brunetti, P Gallotti, E Chiesa, F Testore, A D'Arco, A Ferro, A Jirillo, M Pezzoli, G Scambia, C Iacono, P Masullo, G Tomasello, G Gandini, A Zoboli, C Bottero, M Cazzaniga, G Genua, S Palazzo, M D'Amico, D Perrone

Publikováno v: The Lancet. Oncology. 23(12)

Previous analyses of the GIM (Gruppo Italiano Mammella) 2 study showed that addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel in patients with node-positive early breast cancer does not improve outcome, whereas dose-dense chemo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244272f106167f05f58e0353846fd81d
https://pubmed.ncbi.nlm.nih.gov/36370715

LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

Autor: J. Tabernero, T. Yoshino, T.W. Kim, R. Yaeger, J. Desai, H.S. Wasan, E. Van Cutsem, F. Ciardiello, T. Maughan, C. Eng, J. Tie, M.E. Elez Fernandez, S. Lonardi, X. Zhang, R. Chavira, T. Usari, E. Hahn, S. Kopetz

Publikováno v: Annals of Oncology. 33:S1392-S1393

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b379e142ae48de8f7126b40b11b7db2
https://doi.org/10.1016/j.annonc.2022.08.022